Format

Send to

Choose Destination
Nat Commun. 2016 Jul 6;7:12150. doi: 10.1038/ncomms12150.

Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.

Author information

1
Department of Medicine, University Hospital, University of Verona, Verona 37134, Italy.
2
Department of Otorhinolaryngology, University Hospital Essen, Essen D-45122, Germany.
3
Department of Oncological Sciences, Tisch Cancer Institute, Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA.
4
Department of Experimental Oncology and Molecular Medicine, Molecular Immunology Unit, Fondazione IRCCS Istituto Nazionale dei Tumori, Milano 20133, Italy.
5
New York University School of Medicine, New York, New York 10029, USA.
6
GI-Malignancy Section, Thoracic and GI Oncology Branch, NCI, Bethesda, Maryland 20892, USA.
7
Department of Surgery, Oncology and Gastroenterology, Section of Oncology and Immunology, University of Padova, Padova 35128, Italy.
8
Veneto Institute of Oncology IOV-IRCCS, Padova 35128, Italy.
9
Departments of Infectious Diseases and Immunology, St Jude Children's Research Hospital, Memphis, Tennessee 38105, USA.
10
Stanley S. Scott Cancer Center, Louisiana State University, New Orleans, Louisiana 70112, USA.
11
University of Maryland Baltimore County, Baltimore, Maryland 21250, USA.
12
Georgia Regents University Cancer Center, Augusta, Georgia 30912, USA.
13
Humanitas Clinical and Research Center, Via Manzoni 56, Rozzano, Milan 20089, Italy.
14
Department of Pharmaceutical Sciences, Università del Piemonte Orientale 'Amedeo Avogadro', via Bovio 6, Novara 20089, Italy.
15
Skin Cancer Unit, German Cancer Research Center (DKFZ), Heidelberg 69120, Germany.
16
Department of Dermatology, Venereology and Allergology, University Medical Center Mannheim, Ruprecht-Karl University of Heidelberg, Mannheim 69120, Germany.
17
Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania 19104, USA.
18
Translational Tumor Immunology, The Wistar Institute, Philadelphia, Pennsylvania 19104, USA.

Abstract

Myeloid-derived suppressor cells (MDSCs) have emerged as major regulators of immune responses in cancer and other pathological conditions. In recent years, ample evidence supports key contributions of MDSC to tumour progression through both immune-mediated mechanisms and those not directly associated with immune suppression. MDSC are the subject of intensive research with >500 papers published in 2015 alone. However, the phenotypic, morphological and functional heterogeneity of these cells generates confusion in investigation and analysis of their roles in inflammatory responses. The purpose of this communication is to suggest characterization standards in the burgeoning field of MDSC research.

PMID:
27381735
PMCID:
PMC4935811
DOI:
10.1038/ncomms12150
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center